Purpose: Radiation therapy in low and high doses is known to be associated with the occurrence of late secondary sarcomas. The addition of chemotherapy has not been clearly demonstrated as a contributing factor. We describe three patients with radiation-associated leiomyosarcoma who had also received antimetabolite chemotherapy. Methods: Three cases of leiomyosarcoma occurring 9-27 years after radiation and antimetabolite chemotherapy are presented, along with histopathological details. A Medline search was used to assess prior reports of leiomyosarcoma after radiation. Results: These three cases appear to be the first reported in which leiomyosarcoma followed therapy with radiation and antimetabolites. Discussion: With the increasing use of antimetabolite therapy combined with radiation, there is the potential for more occurrences of leiomyosarcoma or other post-treatment sarcomas.
Introduction
There is a clear association between radiotherapy and an increased risk of development of secondary solid tumors, including sarcomas. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Patients treated with radiotherapy (RT) for Hodgkin's disease have a risk as high as 20% at 20 years, and much of this excess risk is attributable to radiotherapy with or without chemotherapy. 12, 13 Therapeutic radiation for other malignant and benign diseases has also been associated with secondary malignancies, including secondary sarcomas. 14, 17 Numerous histological subtypes of secondary sarcoma have been reported, but the most common have been osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma (MFH), and angiosarcoma. Leiomyosarcoma (LMS) has been reported to occur after radiotherapy, but mostly in single case reports, and several very small series. These LMS have occurred in diverse sites, after 6-35 years, and after treatment for a variety of malignancies. In this report, we describe a series of three patients who developed leiomyosarcoma in the field of therapeutic radiation after 9-27 years. All had also been treated with antimetabolite chemotherapy.
Patients and methods
We performed a Medline search encompassing the dates 1966-2001. Search terms were used to link radiation therapy, chemotherapy, antimetabolites, and Hodgkin's disease to secondary malignancies, solid tumors, sarcoma, and leiomyosarcoma. Reports of radiation-associated leiomyosarcoma were reviewed for elapsed time between RT and secondary leiomyosarcoma, as well as association of chemotherapy with RT. The cases are summarized in Table 1 .
Case reports and results

Case 1
A 71-year-old man was treated in 1984 for rectal cancer with a low anterior resection and postoperative 5-fluorouracil, together with radiotherapy . Additional stains for desmin, muscle specific antigen, keratin, HMB45, and S100 were negative. of radiation is not known). In June 1998 he noted a small mass beneath the left eye. A work-up included a CT scan of the sinuses, which showed a large mass involving the left face in the area of the left maxillary sinus with extensive destruction of the adjacent bony structures and extension into the ethmoid and sphenoid sinuses. A biopsy in October 1998 revealed a high-grade leiomyosarcoma (Fig. 2) . The patient had a dramatic response to three cycles of preoperative doxorubicin and ifosfamide. Surgical excision of the tumor revealed only microscopic deposits of residual LMS. Two additional cycles of chemotherapy were given, and the patient remained free of disease 1 year later.
Case 3
A 76-year-old woman was treated for a T2N0M0 squamous cell carcinoma of the epiglottis in 1989 with laser excision and post-operative infusional 5-FU (800 mg/m 2 per day Â 5 days every other week for six cycles), oral hydroxyurea (1000 twice daily for 5.5 days, every other week for six cycles) and radiation (6000 cGy). In October 1998, the patient presented with dysphagia and stridor; direct laryngoscopy and CT scanning revealed a large, partially obstructing tracheal mass (Fig. 3) . A tracheal stent was placed, and a biopsy revealed a high-grade leiomyosarcoma (Fig. 4) . The mass was unresectable, and she underwent palliative chemotherapy with doxorubicin and dacarbazine in November 1998. She tolerated the chemotherapy well but died within a month of disease progression.
Discussion
We report three cases of radiation associated LMS occurring 9-14 years following RT (or 9-27, as one patient received two separate courses of RT) in three patients who presented to our clinic in the same month. All had received prior antimetabolite therapy: in one case, 5-fluorouracil; in another azathioprine; and in the third, 5-fluorouracil and hydroxyurea. One of these patients also received the alkylating agent cyclophosphamide.
Clear associations have been made between therapeutic RT for cancer and the development of late second malignancies. [1] [2] [3] [4] [5] [6] [7] These associations have also been made for low-dose RT as used in the past for benign conditions such as tonsillar enlargement, menorrhagia, peptic ulcer disease or acne. [8] [9] [10] An excess of hematological malignancies and solid tumors occur above that expected for either agematched controls or disease-matched controls not receiving radiation. Even though soft tissue sarcomas represent only a small percentage of these solid tumors, the excess relative risk at 20 years has been reported to be six-to several hundred-fold greater than expected. 2, 6, 11 Whereas there appears to be a plateau in the incidence of hematological malignancies at 10 years, the peak solid tumor incidence has not been identified, and series with 15-20 year follow-up report a total incidence as high as over 20%. 1, 3, 5, 11, 12 Chemotherapy clearly contributes to the development of secondary hematological malignancies but not as clearly to the development of secondary solid tumors. Lung cancer risk is likely increased by chemotherapy, 2 whereas breast cancer risk appears to be more related to RT than chemotherapy. 1, 13 In several series reporting post-radiation or radiationassociated sarcomas, the most common subtypes have been angiosarcoma, osteosarcoma, fibrosarcoma, and MFH. 10, [15] [16] [17] Leoimyosarcoma has not been commonly reported. We were able to find 33 reports of RT associated LMS in the English language literature, comprising 21 single case reports, four series of two patients 16, [39] [40] [41] and one series of four patients. 10 These 33 leiomyosarcomas occurred 6-35 years after therapeutic RT for a variety of benign and malignant diseases. In the largest series, none of the four patients had received chemotherapy, although several other cases have been reported in association with chemotherapy, mostly alkylating agents. The prognosis for patients with post-radiation solid tumors, and sarcomas in particular, is poor. 16, 42, 43 All three of our cases of radiation-associated LMS, which occurred 9-27 years after RT, presented to our clinic in the same month. All had received prior antimetabolite therapy: in two cases 5-fluorouracil, and in one case azathioprine. It is possible that antimetabolite therapy leads to mis-incorporation of nucleotides or other faulty DNA repair in the setting of RT induced sublethal damage, allowing for later sarcomagenesis in otherwise vulnerable smooth muscle cells. Prior reports of secondary sarcomas have not reported the association of antimetabolite therapy as a contributory factor. There is, however, a long latency period from radiotherapy to second primary sarcoma, so the rise in excess cases may lag behind any increase in antimetabolite plus radiotherapy use. With the increasing evidence for the use of 5-FU as a radiosensitizer in the treatment of malignancies, such as head and neck cancer, cervical cancer, stomach cancer, rectal cancer, and pancreatic cancer, more such cases may be seen in the future.
Conclusions
Leiomyosarcoma may rarely occur as a radiationinduced or associated malignancy. In our series of three patients, LMS occurred late after radiotherapy and all had received antimetabolites either concomitant with RT or close to the time of RT. This association has not been previously reported, but there may be a lag time between the increasing use of treatment with RT plus antimetabolite and the development of LMS.
